Wicki Andreas
Known title: DirectorCIK: 0001511472
Associated companies
Transaction History
| HRMY | ▼ Sell | Open Market | 130 | $8K | 12/14/2022 | View on chart |
| HRMY | ▼ Sell | Open Market | 6,320 | $380K | 12/13/2022 | View on chart |
| HRMY | ▼ Sell | Open Market | 22,391 | $1.4M | 12/12/2022 | View on chart |
| HRMY | ▼ Sell | Open Market | 77,853 | $4.8M | 12/5/2022 | View on chart |
| HRMY | ▼ Sell | Open Market | 10,961 | $659K | 11/15/2022 | View on chart |
| HRMY | ▼ Sell | Open Market | 40,317 | $2.4M | 11/14/2022 | View on chart |
| HRMY | ▼ Sell | Open Market | 95,242 | $5.6M | 11/10/2022 | View on chart |
| HRMY | ▼ Sell | Open Market | 15,301 | $888K | 11/9/2022 | View on chart |
| HRMY | ▼ Sell | Open Market | 18,865 | $1.1M | 11/8/2022 | View on chart |
| HRMY | ▼ Sell | Open Market | 157,950 | $9.3M | 11/4/2022 | View on chart |
| HRMY | ▼ Sell | Open Market | 254,141 | $15.1M | 11/3/2022 | View on chart |
| HRMY | ▼ Sell | Open Market | 164,676 | $9.7M | 11/2/2022 | View on chart |
| HRMY | ▼ Sell | Open Market | 71,447 | $3.8M | 8/10/2022 | View on chart |
| HRMY | ▼ Sell | Open Market | 20,745 | $1.1M | 8/9/2022 | View on chart |
| HRMY | ▼ Sell | Open Market | 486,360 | $26.2M | 8/8/2022 | View on chart |
| HRMY | ▼ Sell | Open Market | 29,482 | $1.5M | 8/5/2022 | View on chart |
| HRMY | ▼ Sell | Open Market | 12,640 | $666K | 8/4/2022 | View on chart |
| HRMY | ▼ Sell | Open Market | 30,464 | $1.6M | 8/3/2022 | View on chart |
| HRMY | ▼ Sell | Open Market | 70,370 | $3.1M | 3/11/2022 | View on chart |
| HRMY | ▼ Sell | Open Market | 75,217 | $3.4M | 3/10/2022 | View on chart |
| HRMY | ▼ Sell | Open Market | 140,000 | $6.4M | 3/9/2022 | View on chart |
| HRMY | ▼ Sell | Open Market | 175,000 | $7.2M | 3/3/2022 | View on chart |
| HRMY | ▼ Sell | Open Market | 328,927 | $13.3M | 3/2/2022 | View on chart |
| HRMY | ▼ Sell | Open Market | 92,501 | $3.7M | 3/1/2022 | View on chart |
| HRMY | ▼ Sell | Open Market | 2,585 | $104K | 12/10/2021 | View on chart |
| HRMY | ▼ Sell | Open Market | 24,683 | $990K | 12/8/2021 | View on chart |
| HRMY | ▼ Sell | Open Market | 1,417 | $58K | 11/17/2021 | View on chart |
| HRMY | ▼ Sell | Open Market | 32,251 | $1.3M | 11/16/2021 | View on chart |
| HRMY | ▼ Sell | Open Market | 35,600 | $1.5M | 11/15/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 12, 2026
HRMY Reports New Phase 3 Data and Maintains Positive Analyst Outlook
HRMY shared new Phase 3 data at the European Narcolepsy Days, adding to its pipeline. Analysts remain upbeat, with Needham keeping a positive stance and a $50 target. The Wakix franchise also offers multiple value drivers. Shares rose 48% recently, yet the stock still trades below its 52‑week low.
HRMY Reports New Phase 3 Data and Maintains Positive Analyst Outlook. HRMY shared new Phase 3 data at the European Narcolepsy Days, adding to its pipeline. Analysts remain upbeat, with Needham keeping a positive stance and a $50 target. The Wakix franchise also offers multiple value drivers. Shares rose 48% recently, yet the stock still trades below its 52‑week low.